

ATTORNEY DOCKET NO.: INVIT1250-5

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Jay M. Short

Art Unit:

1639

Application No.:

09/835,096

Examiner

M. Tran

Filed:

April 12, 2001

Title:

MORPHATIDES: NOVEL SHAPE AND STRUCTURE LIBRARIES

RECEIVED

PATENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AUG 1 9 2003

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT

Sir:

Responsive to the Restriction Requirement mailed June 13, 2003 please consider the following amendments and remarks:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 19 of this paper.

Applicant elects with traverse, Group I, Claims 1, 3-26, 28-29, 31-48, and 77. Furthermore, regarding a scaffold species elections, Applicant elects, with traverse, a nucleic acid scaffold having a 5' and 3' flanking region with a sequence as set out in SEQ ID NOs:1 and 2 and a randomized middle sequence of 36 nucleotides that includes 3 of the 4 bases occurring at similar frequency and one of the four bases occurring at a rare frequency of 5% (i.e. 2 positions). Regarding a number and type of linker, Applicant elects,

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on August 13, 2003, in an envelope addressed to:

Commissioner for Patents, P.O. Box, 1450, Alexandria, VA 22313-

Karen LePari

PATENT Attorney Docket No. INVIT1250-5

In re Application of: Jay M. Short

Application No.: 09/835,096

Filed: April 12, 2001

Page 2 of 21

with traverse, two identical linkers that are formed by reacting phenylboronic acid with salicylhydroxamic acid, each linker being bound to a uridine residue on the scaffold through a 5-position of a uracil base of the uridine residue. Regarding the number and type of agents, Applicant elects, with traverse, two threonine residues each bound to a linker through a carboxyl group on each of the threonine molecules. Regarding a target, Applicant elects, with traverse, a thrombin target. Regarding the type of interaction, Applicant elects, with traverse, a morphatide that binds to, or associates with an agent. Regarding a method for separation, Applicant elects, with traverse, chromatography.